3. Characteristics of platelet rich plasma in the treatment of joint disease at Hanoi Medical University Hospital
Main Article Content
Abstract
The study was conducted to evaluate the composition and safety of platelet-rich plasma (PRP) in the treatment of musculoskeletal diseases at Hanoi Medical University Hospital. This is a prospective descriptive study on 31 research subjects. The results showed that the average number of platelets in the PRP block was 743.61 ± 226.37 G/L. The recovery rate of blood cell types including platelets, red blood cells, and white blood cells in PRP is 75.97%, 0.74%, 6.69% respectively. All PRP after extraction have high purity and has negative test result for infection. All study subjects did not have serious side effects, only 41.9% of study subjects had mild pain after PRP injection. The number of white blood cells in the PRP of the group with mild joint pain after PRP injection was 2.66 ± 1.83 G/L; white blood cells numbers of the group without side effects was 1.36 ± 0.71 G/L. The difference in the number of leukocytes in the PRP between the 2 groups is statistically significant with p < 0.05.
Article Details
Keywords
Platelet-rich plasma, safety, side effects
References
2. Everts P, Onishi K, Jayaram P, et al. Platelet-Rich Plasma: New Performance Understandings and Therapeutic Considerations in 2020. Int J Mol Sci. 2020;21(20):7794. doi:10.3390/ijms21207794
3. Del Pino-Sedeño T, Trujillo-Martín MM, Andia I, et al. Platelet-rich plasma for the treatment of diabetic foot ulcers: A meta-analysis. Wound Repair Regen Off Publ Wound Heal Soc Eur Tissue Repair Soc. 2019;27(2):170-182. doi:10.1111/wrr.12690
4. Kocaoemer A, Kern S, Klüter H, et al. Human AB serum and thrombin-activated platelet-rich plasma are suitable alternatives to fetal calf serum for the expansion of mesenchymal stem cells from adipose tissue. Stem Cells Dayt Ohio. 2007;25(5):1270-1278. doi:10.1634/stemcells.2006-0627
5. Sampson S, Reed M, Silvers H, et al. Injection of Platelet-Rich Plasma in Patients with Primary and Secondary Knee Osteoarthritis: A Pilot Study. Am J Phys Med Rehabil. 2010;89(12):961-969. doi:10.1097/PHM.0b013e3181fc7edf
6. Kim JH, Park YB, Ha CW, et al. Adverse Reactions and Clinical Outcomes for Leukocyte-Poor Versus Leukocyte-Rich Platelet-Rich Plasma in Knee Osteoarthritis: A Systematic Review and Meta-analysis. Orthop J Sports Med. 2021;9(6):232596712110119. doi:10.1177/23259671211011948
7. Alves R, Grimalt R. A Review of Platelet-Rich Plasma: History, Biology, Mechanism of Action, and Classification. Skin Appendage Disord. 2018;4(1):18-24. doi:10.11 59/000477353
8. Magalon J, Chateau AL, Bertrand B, et al. DEPA classification: a proposal for standardising PRP use and a retrospective application of available devices. BMJ Open Sport Exerc Med. 2016;2(1):e000060. doi:10. 1136/bmjsem-2015-000060
9. Patel S, Dhillon MS, Aggarwal S, et al. Treatment With Platelet-Rich Plasma Is More Effective Than Placebo for Knee Osteoarthritis: A Prospective, Double-Blind, Randomized Trial. Am J Sports Med. 2013;41(2):356-364. doi:10.1177/0363546512471299
10. Kon E, Buda R, Filardo G, et al. Platelet-rich plasma: intra-articular knee injections produced favorable results on degenerative cartilage lesions. Knee Surg Sports Traumatol Arthrosc. 2010;18(4):472-479. doi:10.1007/s00 167-009-0940-8